Chang David D 4
4 · Allogene Therapeutics, Inc. · Filed May 20, 2024
Insider Transaction Report
Form 4
Chang David D
DirectorPresident and CEO
Transactions
- Award
Common Stock
2024-05-16$2.90/sh+344,828$1,000,001→ 4,810,106 total
Holdings
- 1,201,108(indirect: See footnote)
Common Stock
- 856,044(indirect: See footnote)
Common Stock
- 856,044(indirect: See footnote)
Common Stock
Footnotes (4)
- [F1]These shares of common stock were acquired directly from Allogene Therapeutics, Inc (the "Issuer") in a registered direct offering.
- [F2]Securities held in the name of the Chang 2006 Family Trust
- [F3]Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
- [F4]Securities held in the name of the RTC 2019 Trust dated October 1, 2019.